marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-08-2024
Viridian Therapeutics Balance Sheet 2011-2024 | VRDN
Annual Balance Sheet Viridian Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-81.8 M | -150 M | - | -45.4 M | -16.5 M | -22.3 M | -37.5 M | -2.3 M | -9.73 M | -5.04 M | 488 K | 22.5 M | - |
Long Term Debt |
20.2 M | 4.64 M | - | - | 4.33 M | 8 M | 9.92 M | - | - | - | - | 42 K | - |
Long Term Debt Current |
843 K | 613 K | 520 K | 455 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 544 K | 4.33 M | 8.07 M | 10.1 M | - | 24 K | 109 K | 259 K | 621 K | - |
Total Current Liabilities |
26.6 M | 33.3 M | 13.6 M | 10.7 M | 10.2 M | 6.73 M | 3.9 M | 4.58 M | 2.47 M | 1.99 M | - | - | - |
Total Liabilities |
48.4 M | 40 M | 16 M | 11.2 M | 14.5 M | 14.8 M | 14 M | 4.58 M | 2.49 M | 2.1 M | 1.65 M | 24.2 M | - |
Deferred Revenue |
288 K | 288 K | 289 K | 301 K | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-726 M | -488 M | -358 M | -279 M | -168 M | -126 M | -93.6 M | -30.6 M | -18 M | -6.64 M | -25.9 M | -21.4 M | - |
Total Assets |
490 M | 435 M | 204 M | 131 M | 30.3 M | 66.1 M | 52.5 M | 4.26 M | 12.9 M | 8.09 M | 3.67 M | 2.78 M | - |
Cash and Cash Equivalents |
103 M | 156 M | 42.3 M | 45.9 M | 24.8 M | 32.6 M | 47.4 M | 3.34 M | 10.8 M | 5.12 M | 209 K | - | - |
Book Value |
442 M | 395 M | 188 M | 120 M | 15.8 M | 51.3 M | 38.5 M | -326 K | 10.4 M | 5.99 M | 2.03 M | -21.4 M | - |
Total Shareholders Equity |
442 M | 395 M | 188 M | 120 M | 15.8 M | 51.3 M | 38.5 M | -61.9 M | 10.4 M | 5.99 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Viridian Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
17.5 M | 20.3 M | 20.2 M | 20 M | 4.71 M | 4.68 M | 4.64 M | 4.61 M | 4.58 M | 1.1 M | 1.2 M | 1.1 M | 1.2 M | 1.6 M | - | - | - | - | 7.67 M | 8.67 M | 9.67 M | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 3.17 M | 3.67 M | 4.17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
56.3 M | 47.9 M | 48.4 M | 45.2 M | 35.6 M | 36.1 M | 40 M | 31.6 M | 27.9 M | 16.5 M | 16 M | 16.6 M | 19.3 M | 16.8 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | 14 M | 14 M | 14 M | 14 M | 9.7 M | 9.7 M | 9.7 M | 9.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
288 K | 288 K | 288 K | 288 K | 288 K | 288 K | 288 K | 288 K | 288 K | 288 K | 289 K | 288 K | 288 K | 288 K | 301 K | - | 301 K | 301 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-839 M | -774 M | -726 M | -659 M | -611 M | -556 M | -488 M | -442 M | -413 M | -384 M | -358 M | -329 M | -315 M | -297 M | -279 M | -279 M | -279 M | -279 M | -168 M | -168 M | -168 M | -168 M | -126 M | -126 M | -126 M | -126 M | -93.6 M | -93.6 M | -93.6 M | -93.6 M | -67.1 M | -67.1 M | -67.1 M | -67.1 M | -18 M | -18 M | -18 M | -18 M | -6.64 M | -6.64 M | -6.64 M | -6.64 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
586 M | 630 M | 490 M | 329 M | 351 M | 387 M | 435 M | 441 M | 170 M | 183 M | 204 M | 221 M | 118 M | 123 M | 131 M | 131 M | 131 M | 131 M | 30.3 M | 30.3 M | 30.3 M | 30.3 M | 66.1 M | 66.1 M | 66.1 M | 66.1 M | 52.5 M | 52.5 M | 52.5 M | 52.5 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 8.09 M | 8.09 M | 8.09 M | 8.09 M | 3.67 M | 3.67 M | 3.67 M | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
108 M | 91.6 M | 103 M | 112 M | 87.1 M | 88.5 M | 156 M | 344 M | 31.3 M | 30.9 M | 42.3 M | 139 M | 27.7 M | 46.5 M | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 24.8 M | 24.9 M | 24 M | 18.2 M | 32.6 M | 31.7 M | 32.6 M | 32.6 M | 47.4 M | 47.4 M | 47.4 M | 47.4 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M | 21.2 M | 10.8 M | 10.8 M | 10.8 M | 5.12 M | 5.12 M | 7.7 M | 5.12 M | 209 K | 209 K | 209 K | - | 113 K | - | - | - | - | - | - | - |
Book Value |
529 M | 583 M | 442 M | 284 M | 316 M | 351 M | 395 M | 409 M | 142 M | 167 M | 188 M | 205 M | 98.9 M | 106 M | 120 M | 120 M | 120 M | 120 M | 15.8 M | 15.8 M | 15.8 M | 15.8 M | 51.3 M | 51.3 M | 51.3 M | 51.3 M | 38.5 M | 38.5 M | 38.5 M | 38.5 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 8.09 M | 8.09 M | 8.09 M | 8.09 M | 3.67 M | 3.67 M | 3.67 M | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
529 M | 583 M | 442 M | 284 M | 316 M | 351 M | 395 M | 409 M | 142 M | 167 M | 188 M | 205 M | 98.9 M | 106 M | 120 M | 120 M | 120 M | 120 M | 15.8 M | 15.8 M | 15.8 M | 15.8 M | 51.3 M | 51.3 M | 51.3 M | 51.3 M | 38.5 M | 38.5 M | 38.5 M | 38.5 M | -61.9 M | -61.9 M | -61.9 M | -61.9 M | -45.3 M | 10.4 M | 10.4 M | 10.4 M | 5.99 M | 5.99 M | 5.99 M | 5.99 M | -23.9 M | - | -23.9 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency